You are here:
Antibiotic resistance is one of the biggest health problems in the world. Around 700,000 people worldwide died of multi-resistant bacteria in 2013. In Germany alone, 11,000 patients died after infection with multi-resistant germs. The global consumption of antibiotics in human medicine increased by almost 40% between 2000 and 2010. According to estimates, 1-2% of the total population in Germany are already carriers of multi-resistant pathogens.
Although fewer antibiotics have been prescribed in recent years, the frequency of pathogens in intensive care units and the use of reserve antibiotics is increasing in Germany. Due to a lack of economic incentives, fewer and fewer antibiotics are being developed. In addition, the time needed to develop resistance to new antibiotics is constantly decreasing.
The aim of the EvolChip project is to develop a device that simulates the development of resistance. In addition, the effectiveness of dynamic antibiotic combinations can be investigated. This helps to avoid the development of resistances and to give therapy recommendations. There is currently no commercial device that predicts future resistance. EvolChip models the pharmacokinetic situation in patients better than previously available processes.